ValuEngine Downgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) to Hold
Deciphera Pharmaceuticals (NASDAQ:DCPH) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, ValuEngine reports.
Other research analysts have also issued research reports about the stock. BidaskClub raised shares of Deciphera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 2nd. Guggenheim upped their price objective on shares of Deciphera Pharmaceuticals from $44.00 to $66.00 and gave the company a “buy” rating in a research report on Tuesday. Deutsche Bank started coverage on shares of Deciphera Pharmaceuticals in a research report on Thursday, July 18th. They set a “buy” rating and a $42.00 price objective for the company. Zacks Investment Research raised shares of Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating and set a $26.00 price objective for the company in a research report on Monday, August 5th. Finally, Piper Jaffray Companies upped their price objective on shares of Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Monday, June 3rd. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company’s stock. Deciphera Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $43.67.
Deciphera Pharmaceuticals stock traded up $15.95 on Tuesday, reaching $35.90. 10,854,326 shares of the stock were exchanged, compared to its average volume of 291,452. The firm has a market cap of $1.44 billion, a PE ratio of -12.73 and a beta of 2.34. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.26 and a current ratio of 7.26. Deciphera Pharmaceuticals has a twelve month low of $18.55 and a twelve month high of $42.99. The company’s fifty day moving average is $22.57.
In related news, CFO Thomas Patrick Kelly sold 1,473 shares of the stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $25.06, for a total value of $36,913.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael Douglas Taylor sold 22,500 shares of the stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $40.77, for a total transaction of $917,325.00. The disclosure for this sale can be found here. Insiders sold 185,607 shares of company stock valued at $7,536,409 in the last three months. Company insiders own 7.02% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Bank of Montreal Can acquired a new position in Deciphera Pharmaceuticals in the second quarter worth about $28,000. BNP Paribas Arbitrage SA grew its stake in Deciphera Pharmaceuticals by 61,033.3% during the first quarter. BNP Paribas Arbitrage SA now owns 1,834 shares of the company’s stock worth $43,000 after buying an additional 1,831 shares during the last quarter. Tower Research Capital LLC TRC bought a new stake in Deciphera Pharmaceuticals during the second quarter worth about $64,000. JPMorgan Chase & Co. grew its stake in Deciphera Pharmaceuticals by 89.2% during the second quarter. JPMorgan Chase & Co. now owns 4,057 shares of the company’s stock worth $95,000 after buying an additional 1,913 shares during the last quarter. Finally, Virtus ETF Advisers LLC grew its stake in Deciphera Pharmaceuticals by 17.7% during the second quarter. Virtus ETF Advisers LLC now owns 12,449 shares of the company’s stock worth $281,000 after buying an additional 1,871 shares during the last quarter. 59.10% of the stock is owned by hedge funds and other institutional investors.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Recommended Story: What is the QQQ ETF?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.